Table 2 Causes of death in the Bonn cohort.
From: Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
Number of deaths | HIV 23 (13.1%) | HIV/HCV 23 (15.8%) |
|---|---|---|
Causes of death | ||
Infections/sepsis | 4# (17.4%) | 3 (13.0%) |
Cardiovascular diseases | 6 (26.1%) | 3 (13.0%) |
Non-AIDS-Malignancies | — | 1 (4.3%) |
Lung cancer | 2 (8.7%) | 1 (4.3%) |
Liver related deaths | 1 (4.3%) | 8 (34.8%) p = 0.03 |
Liver failure | 1 (4.3%) | 2 (8.7%) |
OLTX | — | 2 (8.7%) |
HCC | — | 4 (14.4%) |
Suicide/accidents | 2* (8.7%) | |
Intoxication | 2 (8.7%) | 1 (4.3%) |
AIDS defining conditions | 3 (13.0%) | 3 (13.0%) |
Pneumocytis jeroveci pneumonia | 2 (8.7%) | 2 (8.7%) |
Non-Hodgkin lymphoma | — | 1 (4.3%) |
Castleman’s disease | 1 (4.3%) | — |
Cryptosporidiasis | — | — |
Other causes | — | 2 (8.7%) |
Renal failure | — | 1 (4.3%) |
Bleeding due to Osler’s disease | — | 1 (4.3%) |
Unknown causes of death | 3 (13.0%) | 1 (4.3%) |
